Neoadjuvant therapy becomes increasingly important in comprehensive treatment of breast cancer， especially in locally advanced patients who have a high proportion in China. This consensus， developed by a multidisciplinary expert panel， based on existing evidence-based medical evidence and clinical practice， clarifies key concepts such as efficacy prediction and evaluation of breast cancer neoadjuvant therapy and their application in clinical decision-making through a systematic literature review combined with expert opinions. The consensus proposes a three-dimensional framework of efficacy prediction-dynamic evaluation-comprehensive evaluation， establishes a multidimensional assessment system that incorporates clinical， imaging， pathological and molecular biological information， and emphasizes the implementation of individualized monitoring strategies based on molecular subtypes of breast cancer. The contents include： （1） comprehensive baseline assessment and efficacy prediction methods before treatment； （2） principles of dynamic monitoring and treatment adjustment during treatment； （3） evaluation of therapeutic efficacy and assistance in decision-making； （4） molecular subtype-specific evaluation strategies and key points for long-term follow-up； （5） individualized evaluation protocols for special subtypes and special populations. This consensus aims to provide clinicians with standardized and normalized guidance to facilitate the precision management of breast cancer neoadjuvant therapy， improve efficacy， and enhance patient outcomes.